GCG and metabolic dysfunction-associated steatotic liver disease: In this context, efinopegdutide, a dual GLP-1/glucagon agonist, has been studied in non-alcoholic fatty liver disease (NAFLD), a condition frequently associated with HFpEF, in a phase IIa trial showing greater antagonist reduction in liver fat content when compared with semaglutide (NCT04944992).